Edesa Biotech Recommendation mean
What is the Recommendation mean of Edesa Biotech?
The Recommendation mean of Edesa Biotech, Inc. is 2.00
What is the definition of Recommendation mean?
Recommendation mean is the mean of analysts’ ratings of the stock ranging from 1.0 (strong buy) to 5.0 (strong sell).
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
Recommendation mean of companies in the Health Care sector on NASDAQ compared to Edesa Biotech
What does Edesa Biotech do?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Companies with recommendation mean similar to Edesa Biotech
- Cabot Oil & Gas has Recommendation mean of 1.96
- Truist has Recommendation mean of 1.96
- Delta Air Lines has Recommendation mean of 1.96
- Discover Services has Recommendation mean of 1.96
- United Micro Electronics has Recommendation mean of 1.96
- Tapestry Inc has Recommendation mean of 1.97
- Edesa Biotech has Recommendation mean of 2.00
- Trip.com Ltd has Recommendation mean of 2.03
- Sherwin-Williams Co has Recommendation mean of 2.03
- Canadian Pacific Kansas City has Recommendation mean of 2.03
- Arista Networks Inc has Recommendation mean of 2.03
- Anheuser-Busch InBev SA/NV has Recommendation mean of 2.03
- Celanese Corp has Recommendation mean of 2.04